$1.38 Billion is the total value of Boxer Capital, LLC's 49 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMRN | New | AMARIN CORP PLCspons adr new | $53,060,000 | – | 3,500,000 | +100.0% | 3.85% | – |
| SWTX | New | SPRINGWORKS THERAPEUTICS INC | $45,006,000 | – | 2,075,905 | +100.0% | 3.26% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $41,426,000 | – | 550,000 | +100.0% | 3.00% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $30,330,000 | – | 450,000 | +100.0% | 2.20% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $16,863,000 | – | 700,000 | +100.0% | 1.22% | – |
| ZGNX | New | ZOGENIX INC | $12,012,000 | – | 300,000 | +100.0% | 0.87% | – |
| BLU | New | BELLUS HEALTH INC NEW | $11,342,000 | – | 1,775,000 | +100.0% | 0.82% | – |
| AVRO | New | AVROBIO INC | $8,472,000 | – | 600,000 | +100.0% | 0.61% | – |
| LXRX | New | LEXICON PHARMACEUTICALS INC | $7,525,000 | – | 2,500,000 | +100.0% | 0.55% | – |
| ACHN | New | ACHILLION PHARMACEUTICALS IN | $7,200,000 | – | 2,000,000 | +100.0% | 0.52% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $2,988,000 | – | 400,000 | +100.0% | 0.22% | – |
| RCUS | New | ARCUS BIOSCIENCES INC | $2,730,000 | – | 300,000 | +100.0% | 0.20% | – |
| PRTA | New | PROTHENA CORP PLC | $624,000 | – | 79,598 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 32 | Q3 2023 | 55.2% |
| BEIGENE LTD | 31 | Q3 2023 | 15.6% |
| KURA ONCOLOGY INC. | 24 | Q3 2021 | 4.7% |
| ROCKET PHARMACEUTICALS INC | 23 | Q3 2023 | 5.4% |
| DBV TECHNOLOGIES S A | 23 | Q3 2023 | 3.9% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SYNDAX PHARMACEUTICALS INC | 20 | Q3 2021 | 3.1% |
| GOSSAMER BIO INC | 19 | Q3 2023 | 4.7% |
| ODONATE THERAPEUTICS INC | 18 | Q1 2022 | 12.5% |
| ESPERION THERAPEUTICS INC NE | 18 | Q2 2021 | 11.0% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
| SpringWorks Therapeutics, Inc. | September 19, 2022 | 3,421,541 | 5.7% |
| iTeos Therapeutics, Inc. | May 11, 2022 | 2,154,058 | 6.1% |
| Atreca, Inc. | February 14, 2022 | 2,202,333 | 7.2% |
| Biomea Fusion, Inc. | February 14, 2022 | 1,188,405 | 4.1% |
| Cabaletta Bio, Inc. | February 14, 2022 | 540,000 | 1.9% |
| CymaBay Therapeutics, Inc. | February 14, 2022 | ? | ? |
| DBV Technologies S.A. | February 14, 2022 | 1,067,299 | 1.9% |
| Elevation Oncology, Inc. | February 14, 2022 | 872,780 | 3.8% |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| SC 13D/A | 2024-02-08 |
| 4 | 2024-01-25 |
| SC 13D/A | 2024-01-25 |
| SC 13G | 2024-01-18 |
| SC 13D/A | 2023-12-18 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.